Year All20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 04, 2026 Read More BioCryst Reports Full Year 2025 Financial Results and Provides Business Update Feb 26, 2026 Read More BioCryst to Present at Upcoming Investor Conference Feb 17, 2026 Read More BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting Feb 11, 2026 Read More BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 Feb 05, 2026 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 05, 2026 Read More BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema Jan 23, 2026 Read More BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range Jan 12, 2026 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 06, 2026 Read More BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference Jan 06, 2026 Read More
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update Feb 26, 2026 Read More
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting Feb 11, 2026 Read More
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema Jan 23, 2026 Read More
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range Jan 12, 2026 Read More